NICE updates methods in preparation for "widespread" use of biosimilars
This article was originally published in Scrip
The National Institute for Health and Care Excellence (NICE) has reviewed and updated its methods for providing guidance and advice on biosimilars in preparation for an expected increase in the number of such products coming onto the market. Among other things it says biosimilars could be subject either to a technology appraisal (guidance) or to a less prescriptive "evidence summary".
You may also be interested in...
New guidance from the UK regulator covers distribution and deployment of Pfizer/BioNTech's COVID-19 vaccine, which will be complex because of the temperature storage requirements and the large packs in which the vaccine doses will be delivered.
The UK’s rapid authorization of the Pfizer/BioNTech COVID-19 vaccine has sparked a public debate over regulatory processes at some of the world’s key regulatory bodies.
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.